AUTH/2390/2/11 - Anonymous representative v Alcon

Promotion of Azarga

  • Received
    21 February 2011
  • Case number
    AUTH/2390/2/11
  • Applicable Code year
    2008
  • Completed
    27 April 2011
  • No breach Clause(s)
    2, 9.1, 15.2, 15.9 and 17
  • Additional sanctions
  • Appeal
    No appeal
  • Review
    August 2011

Case Summary

An anonymous Alcon representative complained about the company's alleged unethical promotion of Azarga (brinzolamide/timolol) eye drops for glaucoma. The complainant explained that representatives had been given litmus paper and bottles of Azarga and Cosopt (a competitor product) in order to practically demonstrate the pH differences between the two. The complainant alleged that representatives had been encouraged to instil the eye drops into their own eyes and those of their customers; one doctor had reportedly suffered an adverse event. The complainant stated that representatives were asked by their managers to 'dampen down' on the practice as the competition was upset but submitted that the sensationalism had worked too well for any of his team to stop.

The detailed response from Alcon is given below.

The Panel noted that a complainant had the burden of proving their complaint on the balance of probabilities. Anonymous complaints, like all complaints were judged on the evidence provided by both parties. In this case, the complainant had provided no evidence to support their allegations and as they had also not provided any contact details there was no way to ask them to provide further and better particulars.

The Panel noted that one page of the Azarga detail aid highlighted the difference in pH between Azarga and Cosopt. One of the slides from the representatives' briefing showed bottles of both eye drops and some litmus paper. In the Panel's view it was not unreasonable for representatives to practically demonstrate the pH difference between the two products. It was not unacceptable under the Code for representatives to hold supplies of medicines and Alcon's record of the quantity and destination of all of the eye drops supplied to the field force did not seem incompatible with their use to demonstrate pH differences.

The Panel noted that representatives had been asked to demonstrate the pH differences between Azarga and Cosopt in February 2010, a year before the complaint was received; despite the passage of time the complainant had provided no evidence to show that representatives had been encouraged to instil the eye drops either into their own eyes or those of their customers. Neither had any evidence been provided to show that managers had instructed the representatives to 'dampen down' the practice. The Panel noted Alcon's submission that it was not unusual for an ophthalmologist to unilaterally decide to try eye drops out on themselves so that they knew if, and how much, discomfort each produced on instillation. In thePanel's view it was not unreasonable that the ophthalmologists might report the results back to the representatives.

The Panel noted that the representatives had not been trained on how to instil eye drops. It would have been helpful, given ophthalmologists' propensity to try out eye drops, to have reminded representatives not to let them use the demonstration bottles. However, there was no evidence that representatives had been briefed to instil the eye drops either into their own eyes or those of their customers as alleged and no evidence that representatives had proactively encouraged ophthalmologists to instil the demonstration eye drops. No breach of the Code was ruled.

The eye drops had not been provided as samples and so there could thus be no breach of the Code in that regard.

The Panel noted its rulings above and considered that there was no evidence to show that high standards had not been maintained. No breach of the Code was ruled including no breach of Clause 2.